Ranbaxy, Arrow Face EC Fines For Pay-For-Delay Deals
This article was originally published in PharmAsia News
Ranbaxy Laboratories and New Zealand's Arrow Pharmaceuticals are among nine international drug makers that face European Commission antitrust fine involving pay-for-delay deals to slow introduction of generic drugs.
You may also be interested in...
Swiss biotech Molecular Partners will receive upfront payment of CHF 60m, including equity.
Just as the MDR and IVDR are being implemented, increasing regulatory divergence in Europe is a growing danger to patient safety throughout the EU, not least through increasing costs and impacting device availability.
It’s time to focus on how the diagnostics sector will comply with the EU’s IVD Regulation. TÜV SÜD expert, Andreas Stange, explains why the IVD industry could be in trouble and what must be done now.